BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed) | RFA MH 19 136

Opportunity Information: Apply for RFA MH 19 136

The National Institutes of Health (NIH) BRAIN Initiative funding opportunity titled "Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed)" (Funding Opportunity Number RFA-MH-19-136) supports research projects aimed at creating and rigorously validating new neurotechnology tools that make it possible to study how the brain works at the level of specific cell types and defined neural circuits. The central idea is to push beyond current technical limits so researchers can analyze complex brain circuitry in far greater detail and, as a result, better understand the cellular interactions that drive brain function. Projects are expected to produce tools that either take advantage of, or directly enable, precise cell-type and/or circuit-level targeting, rather than broad, non-specific approaches.

A key expectation is that applicants do not just propose a new method or platform, but also include a clear plan to demonstrate that it works and is genuinely useful. In other words, validation is not a side aim; it is an essential feature of a competitive application. This validation would typically involve demonstrating performance characteristics such as specificity (hitting the intended cell type or circuit), sensitivity (detecting or affecting targets reliably), precision (tight spatial and temporal control), reproducibility, and practical utility in real experimental settings. The opportunity is especially interested in tools that provide major capability jumps, meaning approaches that break through existing barriers rather than offering small incremental improvements.

The initiative explicitly encourages both genetic and non-genetic strategies for delivering genes, proteins, or chemicals to cells of interest, as well as any other approaches that can target specific neuronal or glial populations or defined circuits with higher precision and sensitivity than standard techniques. This emphasis reflects a broader goal of enabling experiments that can dissect causality in brain circuits: being able to label, monitor, manipulate, or perturb the right cells in the right circuit at the right time, and then interpret the results with confidence. While the announcement does not limit the tool types to a short list, the scope is consistent with novel delivery vectors, engineered molecular systems, targeting strategies, and other enabling technologies designed for cell- and circuit-specific access in the nervous system.

Another strong preference in the announcement is for broadly usable tools. Technologies that can be applied across multiple species or model organisms are viewed as especially valuable compared with tools that only work in a single species. This cross-species emphasis supports the BRAIN Initiative goal of producing widely adoptable resources that can accelerate progress across many areas of neuroscience, from basic mechanistic studies to translationally relevant models. Applicants are therefore incentivized to think about portability, generalizability, and the practical constraints that often prevent a tool from being used outside the original development lab.

This opportunity uses the NIH R01 grant mechanism, indicating it is intended for substantial, hypothesis-driven or technology-driven projects with a well-developed research plan and a meaningful scope of work. The listing specifies "Clinical Trial Not Allowed," so applications proposing clinical trials are not eligible under this announcement; the focus is on tool development and validation rather than testing interventions in clinical trial frameworks. The funding instrument type is a grant, and the opportunity sits within NIH activity areas spanning education, health, income security, and social services as categorized in the federal listing, with multiple CFDA numbers associated with NIH programs (including 93.173, 93.213, 93.242, 93.273, 93.279, 93.286, 93.313, 93.853, 93.865, 93.866, 93.867).

Eligibility is broad and includes many types of U.S. and non-U.S. organizations. Eligible applicants listed include state, county, city/township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses); small businesses; and additional entities categorized as "others." The announcement also highlights additional eligible applicant groups such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and foreign (non-U.S.) organizations. This wide eligibility aligns with the BRAIN Initiative's interest in drawing on diverse technical expertise, engineering approaches, and neuroscience perspectives.

From a practical standpoint, a strong application under this opportunity would typically make a compelling case that the proposed tool fills a real gap in current neuroscience capabilities, explain why existing methods are insufficient, and show a realistic development path with clear benchmarks and validation experiments. It would also describe how the tool achieves cell-type and/or circuit specificity, how performance will be measured, and how the resulting technology could be adopted by the broader community, ideally across multiple model systems. The overarching goal is not tool building for its own sake, but tool building that enables new kinds of circuit- and cell-specific experiments that were previously difficult or impossible, thereby accelerating the pace and depth of discovery about how the brain functions.

• The National Institutes of Health in the education, health, income security and social services sector is offering a public funding opportunity titled "BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.173, 93.213, 93.242, 93.273, 93.279, 93.286, 93.313, 93.853, 93.865, 93.866, 93.867.
• This funding opportunity was created on 2018-05-03.
• Applicants must submit their applications by 2020-09-09. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA MH 19 136

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: